Display options
Cite
Kang M, Lee S, Oh JJ, et al. Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy. Prostate Int. 2015;3(4):123-6doi: 10.1016/j.prnil.2015.10.015.
Kang, M., Lee, S., Oh, J. J., Hong, S. K., Lee, S. E., & Byun, S. S. (2015). Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy. Prostate international, 3(4), 123-6. https://doi.org/10.1016/j.prnil.2015.10.015
Kang, Minyong, et al. "Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy." Prostate international vol. 3,4 (2015): 123-6. doi: https://doi.org/10.1016/j.prnil.2015.10.015
Kang M, Lee S, Oh JJ, Hong SK, Lee SE, Byun SS. Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy. Prostate Int. 2015 Dec;3(4):123-6. doi: 10.1016/j.prnil.2015.10.015. Epub 2015 Oct 20. PMID: 26779458; PMCID: PMC4685208.
Copy Download .nbib Format: NLM
Share it on

Prostate Int. 2015 Dec;3(4):123-6. doi: 10.1016/j.prnil.2015.10.015. Epub 2015 Oct 20.

Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy.

Prostate international

Minyong Kang, Sangchul Lee, Jong Jin Oh, Sung Kyu Hong, Sang Eun Lee, Seok-Soo Byun

Affiliations

  1. Department of Urology, Seoul National University Bundang Hospital, Seongnam, South Korea.

PMID: 26779458 PMCID: PMC4685208 DOI: 10.1016/j.prnil.2015.10.015

Abstract

BACKGROUND: The aim of this study was to investigate the effects of surgical castration, particularly delaying the time to entrance of systemic chemotherapy, in castration-resistant prostate cancer (CRPC) patients who were refractory to initial combination androgen deprivation therapy.

MATERIALS AND METHODS: We analyzed the clinical data of 14 CRPC patients diagnosed at Seoul National University Bundang Hospital (SNUBH) from November 2008 through May 2015. After exclusion of three patients, we finally analyzed the baseline characteristics of 11 CRPC patients. We also assessed the delaying time of docetaxel administration, which was defined as response duration, after surgical castration.

RESULTS: After bilateral orchiectomy, the treatment response rate was 45.4% and the median duration of response was 9 months (range 4-48 mo). Responders had less aggressive biopsy Gleason scores compared to nonresponders. Notably, responders showed the reducing pattern of serum prostate specific antigen levels, while nonresponders demonstrated increasing tendency after surgical castration. Moreover, responders also presented with a reduction pattern of serum testosterone levels, whereas nonresponders showed an increasing pattern of testosterone levels after bilateral orchiectomy.

CONCLUSIONS: In summary, despite the limited number of cases for convincing evidence, our results shed light again on the clinical benefits of surgical castration prior to the systemic chemotherapy in some CRPC patients after initial hormone therapy.

Keywords: Castration-resistant prostate cancer; Clinical benefits; Surgical castration; Taxane-based chemotherapy

References

  1. Can Urol Assoc J. 2015 Mar-Apr;9(3-4):90-6 - PubMed
  2. J Urol. 2005 Sep;174(3):893-7 - PubMed
  3. Urology. 1991 Jan;37(1):17-21 - PubMed
  4. Adv Urol. 2012;2012:979154 - PubMed
  5. N Engl J Med. 2004 Oct 7;351(15):1502-12 - PubMed
  6. J Clin Oncol. 2014 Oct 20;32(30):3436-48 - PubMed
  7. J Clin Oncol. 2008 Jan 10;26(2):242-5 - PubMed
  8. J Urol. 2000 Sep;164(3 Pt 1):726-9 - PubMed
  9. Urology. 1995 Aug;46(2):220-6 - PubMed
  10. Int J Urol. 2002 Jun;9(6):359-61 - PubMed
  11. J Urol. 2013 Aug;190(2):429-38 - PubMed
  12. Future Oncol. 2014 May;10(7):1113-5 - PubMed
  13. Cancer Res. 2007 May 15;67(10):5033-41 - PubMed
  14. Can J Urol. 2014 Apr;21(2 Supp 1):7-13 - PubMed
  15. Can Urol Assoc J. 2013 Mar-Apr;7(3-4):E226-30 - PubMed
  16. Urol Int. 2006;77(2):135-8 - PubMed
  17. Eur Urol. 2014 Feb;65(2):467-79 - PubMed
  18. Cancer Res. 2001 Apr 1;61(7):2892-8 - PubMed
  19. Rev Urol. 2012;14(1-2):1-12 - PubMed
  20. Endocr Relat Cancer. 2004 Sep;11(3):459-76 - PubMed
  21. Hematol Oncol Clin North Am. 2013 Dec;27(6):1221-41, viii - PubMed
  22. BJU Int. 2012 Jun;109 Suppl 6:1-12 - PubMed
  23. J Clin Oncol. 2005 May 20;23(15):3343-51 - PubMed
  24. S Afr Med J. 2006 Sep;96(9):810-1 - PubMed
  25. Eur Urol. 2012 Jan;61(1):11-25 - PubMed
  26. Can Urol Assoc J. 2010 Dec;4(6):380-4 - PubMed

Publication Types